Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 2Q08

2Q Revenues: $8.0 billion (+9%, +2% at Constant Exchange Rate)

2Q Earnings: $1.6 billion (+13%, +6% CER)

YTD Revenues: $15.6 billion (+10%, +3% CER)

YTD Earnings: $3.1 billion (+4%, -3% CER)

Comments: Sales were buoyed by 35%/27% growth in Crestor, which reached $916 million in 2Q08. Toprol sales plummeted 55%/58% in the quarter, while Nexium sales plateaued at $1.3 billion. Symbicort sales rose 25%/12% to $518 million and Pulmicort was up 20%/14% to $383 million. AZ took a charge of $131 million for restructuring in the quarter; the current restructuring program has now amounted to $1.2 billion in charges.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters